Rimon P.C. acted as U.S. legal counsel to Australian Oilseeds. Ellenoff Grossman & Schole LLP acted as U.S. legal counsel to EDOC. Olshan Frome Wolosky LLP...
You must be a Standard 1 Year member to access this content.
Olshan Frome Wolosky represented Tallan in the transaction. Ernst & Young LLP (EY US) announced that Tallan, Inc., a technology solutions company, is joining the Microsoft...
You must be a Standard 1 Year member to access this content.
Olshan Frome Wolosky LLP represented Jeffrey R. Westphal, Latham & Watkins LLP represented Vertex and Skadden, Arps, Slate, Meagher & Flom LLP represented Goldman Sachs. Jeffrey...
You must be a Standard 1 Year member to access this content.
Olshan Frome Wolosky represented ImmunityBio in the transaction. ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has entered into a definitive agreement to acquire a leasehold interest in 409,000...
You must be a Standard 1 Year member to access this content.
Olshan Frome Wolosky represented P10 in the transaction, while Davis Polk advised the representatives of the several underwriters. P10, Inc., a leading private markets solutions provider, announced...
You must be a Standard 1 Year member to access this content.
Olshan Frome Wolosky LLP advised Anebulo Pharmaceuticals on the deal. Anebulo Pharmaceuticals, Inc. executed its $21 million initial public offering and listing on The Nasdaq Capital Market...
You must be a Standard 1 Year member to access this content.
Olshan Frome Wolosky LLP advised Anebulo Pharmaceuticals on the deal. Anebulo Pharmaceuticals, Inc. executed its $21 million initial public offering and listing on The Nasdaq Capital Market...
You must be a Standard 1 Year member to access this content.
Olshan Frome Wolosky LLP represented Summit Therapeutics in the offering. Summit Therapeutics Inc. (NASDAQ: SMMT) executed its rights offering of up to 14,312,977 shares of its...
You must be a Standard 1 Year member to access this content.
Olshan Frome Wolosky LLP advised IMAC Holdings on the offering. IMAC Holdings, Inc. (Nasdaq: IMAC) executed a $19.55 million underwritten follow-on public offering of its shares...
You must be a Standard 1 Year member to access this content.
